BLOG

NK Cell Therapy Alongside Chemotherapy or Radiation: Questions to Ask

Published 2026.10.18 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you or a family member is already receiving surgery, chemotherapy or radiation therapy, it is natural to wonder whether an additional immune-based option could be considered at the same time. NK cell therapy is one such option. This article explains how the idea of combining it with standard cancer treatment is usually framed, and which questions are worth bringing to your doctors.

Grand Green Osaka Umekita Clinic in Osaka provides NK cell therapy as a cancer immune cell therapy. Nothing here is medical advice, and no outcome can be promised. Whether any combination makes sense for you has to be decided by the doctors who know your diagnosis and treatment plan.

Short answer: it is discussed as an addition, not a replacement

NK cell therapy is described by the clinic as a treatment that can be used alongside surgery, chemotherapy or radiation therapy, not instead of them. Standard treatment remains the foundation of cancer care, and its benefits have been studied far more extensively than those of most immune cell therapies.

The clinic’s information describes the therapy as intended to be compatible with these standard treatments and that coordination with the medical institution providing your standard care is possible. Even so, the final judgment about timing and suitability belongs to your oncologist and the physician at the clinic together, based on your own medical situation.

What NK cells are and what the therapy involves

NK (natural killer) cells are a type of innate immune cell. They circulate in the body and can recognize and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. Researchers have also reported that NK cell activity can decline with age, stress and the effects of cancer itself.

In NK cell therapy, a sample of your own blood is taken in a standard blood draw. The NK cells are then activated and expanded at a specialized cell processing facility, and returned to your body by intravenous infusion. Because the cells come from you, the risk of rejection is thought to be low, although temporary reactions such as fever or fatigue may occur. The treatment is an outpatient procedure that does not require hospitalization.

The goal is to reinforce immune function by returning more NK cells with higher activity. It is important to understand that this is a goal of the approach, not a guaranteed result for any individual patient.

Why timing with standard treatment needs a careful conversation

Cancer treatment is planned as a sequence. Surgery, drug therapy and radiation each have their own schedule, recovery periods and monitoring. Adding another treatment raises practical questions that no general article can answer for you.

Which part of your treatment plan is happening now, and which parts are coming next?
Could the schedule for blood collection, cell culture and infusion overlap with chemotherapy cycles or radiation sessions?
Are there blood test values or physical conditions your oncologist wants to watch before adding anything new?
Who will monitor you for side effects, and how will the two teams share information?

Cell expansion takes time, so planning ahead is usually more practical than deciding at the last minute. Bringing your treatment schedule and recent test results to the consultation allows the physician to give a more concrete and realistic opinion.

Evidence, limits and honest expectations

Research on NK cells and cell-based immunotherapy is active, and you can search public databases such as PubMed to see the kinds of studies that exist. However, results differ by cancer type, cell preparation method, patient condition and study design. A single study should not be read as a general rule, and early-stage findings do not automatically translate into benefit in everyday practice.

NK cell therapy is not a substitute for standard treatment, and it is not a way to avoid it. Be cautious about any explanation that suggests otherwise, or that promises a cure. A trustworthy clinic will describe both what the therapy aims to do and what is still uncertain, and will encourage you to keep working with your primary oncology team.

Regulation, cost and what to confirm before you decide

In Japan, NK cell therapy is offered as a self-pay treatment that is not covered by national health insurance. Cell therapies of this kind are provided under the Act on the Safety of Regenerative Medicine, which requires that a treatment plan be reviewed by a certified committee and submitted to the Ministry of Health, Labour and Welfare, and that cells be processed at licensed facilities. Asking to have this framework explained is reasonable for any patient.

Because the treatment is self-pay, you should confirm fees, the number of infusions, the expected treatment period, possible risks and side effects, and whether you are a suitable candidate. Fees, risks and eligibility are all confirmed in a consultation with a doctor, and they may differ from person to person. Please review the fee information provided by the clinic and ask for anything you do not understand to be explained in writing where possible.

Is the treatment provided under a regenerative medicine plan submitted under this Act, and can I understand its outline?
What are the total costs, including any items outside the main course?
What temporary reactions have been observed, and what is the plan if they occur?
Can the clinic share information with my current hospital if I agree?

Consulting in Osaka, including from overseas

Osaka and the Umeda area are easy to reach from other parts of Japan and from abroad. Grand Green Osaka Umekita Clinic has information pages in multiple languages, so international patients and residents can review the basics in advance and prepare their questions. If you live outside Japan, think early about how your home oncologist and the clinic will exchange records, and about how follow-up will work after you return.

A first consultation is a chance to ask questions rather than a commitment to start. Bring your diagnosis summary, current treatment schedule and a list of medicines. With those, the physician can discuss whether NK cell therapy could reasonably fit alongside your standard treatment, and what the limits are in your case.

In summary, NK cell therapy is discussed as an option that may be used together with standard cancer treatment, but it is not a replacement and no result can be guaranteed. Clear information on timing, evidence, regulation, fees and risks, together with open communication between your doctors, is the best basis for a decision.

Before Combining Treatments

Standard care stays central
Check treatment timing
Confirm self-pay fees
Decide with your doctors

This figure is a conceptual summary of the article

Learn more about NK Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›